The ProSep-vA Ultra range offers high binding capacity at high flow rates, which improves throughput and productivity.
The media uses the same immobilization chemistry as Millipore's ProSep-A High Capacity media, currently used in the manufacture of several licensed monoclonal therapeutic antibodies.
This proven technology applied on a controlled pore glass (CPG) base matrix with smaller pore size, offers increased surface area and higher dynamic capacity. As a result, the new media provides improved process economics and greater process design flexibility, claims Millipore.
For more information about the new product, visit the company's website
